Yamazaki Tomomi, Cerdeira Ana Sofia, Teraoka Yuko, Oomori Yuriko, Mukai Yurika, Sugimoto Jun, Koh Iemasa, Banno Kouji, Vatish Manu, Kudo Yoshiki
Department of Obstetrics and Gynecology, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan.
Nuffield Department of Women's Health and Reproductive Research University of Oxford Level 3, Women's Center, John Radcliffe Oxford University Hospital Oxford, Oxford, United Kingdom.
Hypertens Res. 2025 Aug 4. doi: 10.1038/s41440-025-02282-0.
Obstetric care in Japan is organized in 3 levels and half of all deliveries are conducted at primary facilities without neonatal intensive care unit. We evaluated the predictive accuracy of the sFlt-1/PlGF ratio for the onset of preeclampsia and adverse outcomes in pregnant women with suspected preeclampsia at multiple facilities in Japan, including primary facilities. 356 pregnant women from 18 + 0 to 36 + 6 weeks of pregnancy were enrolled. 303 women were included in the final analysis. The negative predictive value for ruling out preeclampsia within 1 week using the cut-off value 38 was 98.4% (95% CI, 96.2-99.3) with a negative likelihood ratio of 0.22 (95% CI, 0.09-0.53). The positive predictive value for ruling in preeclampsia within 4 weeks using the cut-off value 38 was 48.2% (95% CI, 38.0-58.5). The positive predictive value using a cut-off value of 85 was 65.0% (95% CI, 44.1-81.4) with a positive likelihood ratio of 12.21 (95% CI, 5.20-28.80). The positive predictive value for prediction of adverse outcomes within 4 weeks using the cut-off value 38 was 64.8% (95% CI, 53.1-75.0). To clarify the accuracy of the test currently covered by insurance in Japan, we additionally conducted an analysis focusing on pregnant women between 18 + 0 and 35 + 6 weeks, yielding even higher accuracy. Pregnant women with sFlt-1/PlGF ratio >38 should be referred to a higher-level medical institution. The appropriate use of sFlt-1/PlGF supported by a robust collaboration between primary and tertiary care institutions may help to improve perinatal outcomes in Japan.
日本的产科护理分为三个级别,所有分娩中有一半是在没有新生儿重症监护病房的初级医疗机构进行的。我们评估了可溶性血管内皮生长因子受体-1(sFlt-1)与胎盘生长因子(PlGF)比值对日本多个医疗机构(包括初级医疗机构)疑似子痫前期孕妇子痫前期发病及不良结局的预测准确性。纳入了356名妊娠18⁺⁰至36⁺⁶周的孕妇。最终分析纳入了303名女性。使用截断值38在1周内排除子痫前期的阴性预测值为98.4%(95%置信区间,96.2 - 99.3),阴性似然比为0.22(95%置信区间,0.09 - 0.53)。使用截断值38在4周内确诊子痫前期的阳性预测值为48.2%(95%置信区间,38.0 - 58.5)。使用截断值85的阳性预测值为65.0%(95%置信区间,44.1 - 81.4),阳性似然比为12.21(95%置信区间,5.20 - 28.80)。使用截断值38在4周内预测不良结局的阳性预测值为64.8%(95%置信区间,53.1 - 75.0)。为了阐明目前日本保险涵盖的该项检测的准确性,我们额外对妊娠18⁺⁰至35⁺⁶周的孕妇进行了分析,结果显示准确性更高。可溶性血管内皮生长因子受体-1与胎盘生长因子比值>38的孕妇应转诊至上级医疗机构。初级和三级医疗机构之间强有力的合作支持下对可溶性血管内皮生长因子受体-1与胎盘生长因子比值的合理应用可能有助于改善日本的围产期结局。